Clinical Impact of New Data From Boston 2016
Source: 2016 Annual Meeting of the American Association for the Study of Liver Diseases*

Module

In this Expert Analysis, Ira M. Jacobson, MD, and Stefan Zeuzem, MD, provide expert interpretation of the most clinically important new data on HCV, HBV, and NASH from this important annual conference.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Integrate the results of recent clinical studies of approved HCV, HBV, and other liver disease therapies into patient management strategies
  • Evaluate the impact of results of clinical studies of investigational treatments for chronic hepatitis C and B on future patient management strategies
  • Implement new data on strategies for diagnosing and managing NAFLD/NASH
  • Incorporate the results of recent studies into the prevention and management of the clinical sequelae of advanced liver disease

Topics covered include:

  • Introduction
  • HCV Treatment: Investigational Regimens
  • HCV Treatment: Real-World Studies With Approved Therapies
  • HBV Studies
  • NASH: Investigational Therapeutics
  • Key Takeaways and Concluding Remarks
 

Faculty

  • Ira M. Jacobson
    MD
    Stefan Zeuzem
    MD

Credit Information

  • Release Date:
    February 01, 2017
  • Expiration Date:
    January 31, 2018
  • Physicians:
    maximum of 1.0 AMA PRA Category 1 Credit
  • Registered Nurses:
    1.0 Nursing contact hour

Information on this Educational Activity

Disclosure of Conflicts of Interest

The Annenberg Center assesses conflict of interest with its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. All relevant conflicts of interest that are identified are thoroughly vetted by the Annenberg Center for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. The Annenberg Center is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Faculty

Ira M. Jacobson, MD


Chair, Department of Medicine
Mount Sinai Beth Israel
Professor of Medicine and Vice-Chair, Department of Medicine
Icahn School of Medicine at Mount Sinai
New York, New York

Ira M. Jacobson, MD, has disclosed that that he has served as a consultant or on advisory boards for AbbVie, Bristol-Myers Squibb, Gilead Sciences, Intercept, Janssen, Merck, and Trek; has served on speaker bureaus for AbbVie, Gilead Sciences, Intercept and Merck; and has received funds for research support from AbbVie, Gilead Sciences, Genfit, and Merck.

 

Stefan Zeuzem, MD


Professor of Medicine
Chief, Department of Medicine I
JW Goethe University Hospital
Frankfurt, Germany

Stefan Zeuzem, MD, has disclosed that he has served as a consultant or on advisory boards for AbbVie, Bristol-Myers Squibb, Gilead Sciences, Janssen, and Roche.

 

Staff

Zachary Schwartz, MSc, ELS


Managing Editor

Zachary Schwartz, MSc, ELS, has no real or apparent conflicts of interest to report.
 

Megan K. Murphy, PhD


Clinical Editor

Megan K. Murphy, PhD, has no real or apparent conflicts of interest to report.
 

Jenny Schulz, PhD


Editorial Director, Virology & Other Therapeutic Areas

Jenny Schulz, PhD, has no real or apparent conflicts of interest to report.
 

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

The following planners and managers, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CHCP, Judi Smelker-Mitchek, RN, BSN and Jan Schultz, RN, MSN, CHCP, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

Charles E. Willis, MBA, Director of Continuing Education, Amanda Sewell, MBA, Manager of Continuing Education, Debbie Price, Registration Database Administrator, and Alma Perez, Accreditation Specialist from the Annenberg Center for Health Sciences at Eisenhower have no relevant commercial relationships to disclose.

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The Annenberg Center, Postgraduate Institute for Medicine (PIM), Clinical Care Options, and activity supporters do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the Annenberg Center, PIM, Clinical Care Options, and activity supporters. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

 

Target Audience

This program is intended for physicians including infectious diseases specialists, hepatologists, and gastroenterologists, registered nurses, and other healthcare professionals involved in the care of patients with liver disease.


Goal

The goal of this activity is to improve participants’ competence in translating the most clinically significant hepatology data from the Boston 2016 conference into practical management strategies for patients with liver diseases.


Learning Objectives

Upon completion of this activity, participants should be able to:

  • Integrate the results of recent clinical studies of approved HCV, HBV, and other liver disease therapies into patient management strategies
  • Evaluate the impact of results of clinical studies of investigational treatments for chronic hepatitis C and B on future patient management strategies
  • Implement new data on strategies for diagnosing and managing NAFLD/NASH
  • Incorporate the results of recent studies into the prevention and management of the clinical sequelae of advanced liver disease
 

Physician Continuing Medical Education

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC. The Annenberg Center for Health Sciences at Eisenhower is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation

The Annenberg Center for Health Sciences at Eisenhower designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

 

Nursing Continuing Education

Accreditation Statement

Annenberg Center for Health Sciences is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

Credit Designation

1.0 contact hour may be earned for successful completion of this activity.

 

Commercial Support


This program is supported by educational grants from Merck & Co., Inc., Gilead Sciences, and AbbVie.

 

Program Medium


This program has been made available online.

 

Site Requirements


  • Internet Explorer 7+, Firefox 3+, Safari 3+, or Chrome
  • JavaScript enabled
  • 1024x768+ screen resolution
  • Adobe Flash Player
 

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1 hour. To successfully complete this activity and receive credit, participants must follow these steps during the period from February 01, 2017, through January 31, 2018:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME activities completed can be found on the "CME Manager" page. There are no costs/fees for this activity.

  • How Recent Guideline Updates on HBV Screening in HCV-Infected DAA Recipients Affect Clinical Practice

    Norah Terrault MD, MPH - 11/23/2016    1 comment / Last Comment: 11/29/2016
    How do recent AASLD/IDSA updates on HBV screening change nonspecialist and specialist management of HCV patients? Here’s my take.
  • Weighing the Treatment Options for Genotype 3 HCV Infection in Cirrhotics

    Mark S. Sulkowski MD - 2/25/2016    3 comments / Last Comment: 4/11/2016
    In my practice, it is the patient with cirrhosis and genotype 3 HCV infection who causes me to pause and carefully consider the patient’s treatment options.
  • How Data From the 2016 Boston Hepatology Meeting Will Influence Future HCV Patient Management

    Mark S. Sulkowski MD - 1/31/2017    2 comments / Last Comment: 4/24/2017
    The 2016 hepatology meeting in Boston offered future solutions to some of my most vexing patient challenges.
  • Why I am Encouraged by Data on NASH Management From the 2016 Boston Hepatology Meeting

    Brent A. Neuschwander-Tetri MD - 3/10/2017    
    The treatment of NASH has challenges not seen in patients with HCV infection, but new trends are emerging.
  • Hepatitis B Reactivation: Sometimes Scratching the Surface May Be Better Than Getting to the Core

    Jordan J. Feld MD, MPH - 1/24/2017    2 comments / Last Comment: 2/21/2017
    Does the need for HBV reactivation screening vary by the potency of immunosuppressive therapy? Here’s my take.